First Experiences With Intravenous Treprostinil Delivered by an Implantable Pump (Lenus Pro®) With Filling Intervals of 28 Days in Patients With Pulmonary Arterial Hypertension (PAH) - A Series of Five Case

PURPOSE: Subcutaneous (s.c.) Treprostinil (Remodulin®) is an established treatment for PAH. Infusion site pain leads to discontinuation of treatment in about 15%. Intravenous (i.v.) administration of prostanoids using external pumps is problematic with regard to infections.